LFCR
Lifecore Biomedical, Inc.7.71
-0.17-2.16%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A quantifies guide headwinds, capacity tightness
Q&A unpacked 2026 guidance headwinds, quantifying $10M HA drop from customer inventory normalization and $7M annualized hit from a lost client, yet offset by largest customer's 2027 aseptic doubling. Commercial site transfers face 24-30 month timelines due to pre-approval inspections, but boast 8-figure peak potential each. Fill/finish capacity stays tight for prefilled syringes, not vials. Asia leads inbound only, no expansion planned. Free cash flow eyes over $10M with $8M CapEx. Management stayed confident; investors track pipeline delays, customer transitions.
Key Stats
Market Cap
288.87MP/E (TTM)
-Basic EPS (TTM)
-1.27Dividend Yield
0%Recent Filings
8-K
Lifecore posts strong transition results
Lifecore Biomedical reported Q4 and seven-month transition period revenues of $35.7M and $75.5M, up 10% and 20% year-over-year, with gross margins expanding to 31% from 26% on cost cuts slashing op ex 31% to $24.4M. Adjusted EBITDA hit $13.1M, versus $2.6M prior. Signed five new programs. 2026 guides $120-125M revenue, yet anticipates customer loss.
8-K
Fiscal year changed to calendar
Lifecore Biomedical shifted to a calendar-year fiscal cycle effective May 26, 2025, ending December 31, aligning SEC filings and annual meetings with standard timing. The 2026 Annual Meeting is now set for June 4, 2026—more than 30 days from last year's October 29 date. Shareholder proposals due by March 16, 2026. Deadline moved sharply.
8-K
Lifecore adopts bonus plan
Lifecore Biomedical's Compensation Committee adopted the Incentive Bonus Plan on January 14, 2026, effective immediately, tying cash bonuses for executives and select employees to financial, operational, and strategic performance targets like net sales and EBITDA. The committee sets targets, weights, and payouts—zero if thresholds miss—while retaining discretion for adjustments on acquisitions or unusual events. Payouts hit by March 15 post-performance period. Plan aligns pay with results.
8-K
Lifecore unveils CDMO growth plan
Lifecore Biomedical furnished an investor presentation at the Jefferies Global Healthcare Conference, highlighting its sterile injectable CDMO strategy amid a fiscal year shift to calendar-end December 31, effective May 26, 2025. FY 2025 delivered $128.9M revenue and $19.5M Adjusted EBITDA; transition period guides $74-76M revenue, $12-14M Adjusted EBITDA. Targets 12% revenue CAGR, 25%+ margins mid-term. Pipeline holds $150-200M potential.
8-K
Q1 revenue jumps 26%
Lifecore Biomedical posted $31.1M revenue for Q1 ended September 30, 2025, up 26% from $24.7M prior year, fueled by HA manufacturing demand and new programs. Gross profit hit $7.8M while SG&A plunged to $8.9M from $14.8M; Adjusted EBITDA swung to $3.1M positive. Revenue grows fast. Affirming $74-76M transition period guidance amid efficiency gains.
IPO
Website
Employees
Sector
Industry
BHC
Bausch Health Companies Inc.
6.93+0.02
BIOE
Bio Essence Corp.
0.05+0.00
CRLBF
Cresco Labs Inc.
1.75+0.45
FLGC
Flora Growth Corp.
8.84+0.39
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
INCR
Intercure Ltd.
1.45+0.05
LEEEF
LEEF BRANDS INC
0.22+0.02
LIFD
LFTD Partners Inc.
0.28+0.00
LVRLF
CordovaCann Corp.
0.03+0.00
RGC
Regencell Bioscience Holdings L
16.70-0.56